CYP-LAD

CYP-LAD
Clinical data
Other namesN,N-Diethyl-6-cyclopropyl-6-norlysergamide; 6-Cyclopropyl-6-norlysergic acid diethylamide; 6-Cyclopropyl-6-nor-LSD; TRALA-22; 6-Cyclopropyl-N,N-diethyl-9,10-didehydroergoline-8β-carboxamide
Identifiers
  • (6aR,9R)-7-cyclopropyl-N,N-diethyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC22H27N3O
Molar mass349.478 g·mol−1
3D model (JSmol)
  • CCN(CC)C(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C5CC5
  • InChI=1S/C22H27N3O/c1-3-24(4-2)22(26)15-10-18-17-6-5-7-19-21(17)14(12-23-19)11-20(18)25(13-15)16-8-9-16/h5-7,10,12,15-16,20,23H,3-4,8-9,11,13H2,1-2H3/t15-,20-/m1/s1
  • Key:LICTYPNIKGFVGH-FOIQADDNSA-N
  (verify)

CYP-LAD, also known as 6-cyclopropyl-6-nor-lysergic acid diethylamide or as TRALA-22, is a lysergamide and analogue of lysergic acid diethylamide (LSD).[1] It was patented by Daniel Trachsel and colleagues in 2023 as an LSD analogue with modified LSD-like action,[1] and had also previously been claimed in a 2022 patent by Gilgamesh Pharmaceuticals.[2]

See also

References

  1. ^ a b US 2023/0414583, Trachsel D, Liechti ME, Lustenberger F, "Lysergic acid derivatives with modified LSD-like action", published 28 December 2023, assigned to Mind Medicine Inc. 
  2. ^ Kruegel AC. Novel Ergolines and Methods of Treating Mood Disorders. Patent WO 2022/226408



This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.